<div id="readability-page-1"><h3>End of Quarter Sale - 50% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>WuXi XDC Cayman, Inc. ( (HK:2268) ) just unveiled an update. WuXi XDC Cayman Inc. and BioDlink International Company Limited announced the close of voluntary conditional cash offers for WuXi XDC shares and share options, which were made on behalf of the offeror by Citigroup Global Markets Asia. The offeror secured valid acceptances for about 61.47% of WuXi XDC’s issued share capital and approximately 99.74% of outstanding share options, resulting in majority control and the cancellation of most options, reshaping the company’s ownership and capital structure. Following completion and subject to registration of transfers, the offeror and its concert parties now control roughly 61.47% of WuXi XDC’s voting rights, consolidating influence over corporate decisions. The offers were neither revised nor extended past the 31 March 2026 deadline, leaving only 20,000 share options outstanding and signaling a completed change of control that may affect minority shareholders’ position and future governance dynamics. The most recent analyst rating on (HK:2268) stock is a Buy with a HK$82.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page. More about WuXi XDC Cayman, Inc. WuXi XDC Cayman Inc. is a Cayman Islands–incorporated company associated with the biopharmaceutical sector through its linkage with BioDlink International Company Limited, a Hong Kong–incorporated firm. The companies are listed in Hong Kong and are involved in equity and option-based shareholding structures that attract strategic investment activity. Average Trading Volume: 4,511,532 Technical Sentiment Signal: Sell Current Market Cap: HK$74.1B </div>

513060

588130

512290

WuXi XDC Cayman, Inc. has completed voluntary cash offers, securing 61.47% of its issued share capital and 99.74% of outstanding share options, granting majority control to the offeror. This change in ownership will reshape the company's capital structure and influence corporate decisions. The offers were not extended beyond the March 31, 2026 deadline, leaving only 20,000 share options outstanding. The latest analyst rating for WuXi XDC (HK:2268) is a Buy with a price target of HK$82.00.

Tip Ranks

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

WUXI XDC

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

WuXi XDC Cash Offers Close With Offeror Gaining Majority Control